Nanalysis Scientific Corp
XTSX:NSCI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.335
0.58
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Nanalysis Scientific Corp
Nanalysis Scientific Corp
Cost of Revenue
Nanalysis Scientific Corp
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nanalysis Scientific Corp
XTSX:NSCI
|
Cost of Revenue
-CA$24.5m
|
CAGR 3-Years
-108%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Titan Medical Inc
TSX:TMD
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Profound Medical Corp
TSX:PRN
|
Cost of Revenue
-$3.1m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Opsens Inc
TSX:OPS
|
Cost of Revenue
-CA$20.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-16%
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Cost of Revenue
-CA$469.6k
|
CAGR 3-Years
11%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-1%
|
|
|
MedMira Inc
XTSX:MIR
|
Cost of Revenue
-CA$143.3k
|
CAGR 3-Years
41%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
20%
|
|
Nanalysis Scientific Corp
Glance View
Nanalysis Scientific Corp. is a capital pool company, which engages in the development and manufacture of portable nuclear magnetic resonance (NMR) spectrometers for the laboratory instrumentation market. The company is headquartered in Calgary, Alberta. The company went IPO on 2017-06-29. The firm operates through three segments: Nanalysis, RS2D and Corporate. Through its European subsidiary RS2D S.A.S. (RS2D), the Company also manufactures and distributes electronic boards and software are used in nuclear magnetic resonance (NMR) and MRI equipment. Its 60 and 100 megahertz (MHz) spectrometers incorporate permanent magnets and require no liquid helium or other cryogens. Its spectrometers are used by chemical professionals spanning industries, including oil and gas, chemical, mining, pharmaceutical, and biotechnology. The Company’s product offerings are based upon its magnet technology, as well as its Cam4 technology.
See Also
What is Nanalysis Scientific Corp's Cost of Revenue?
Cost of Revenue
-24.5m
CAD
Based on the financial report for Dec 31, 2023, Nanalysis Scientific Corp's Cost of Revenue amounts to -24.5m CAD.
What is Nanalysis Scientific Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-52%
Over the last year, the Cost of Revenue growth was -79%. The average annual Cost of Revenue growth rates for Nanalysis Scientific Corp have been -108% over the past three years , -52% over the past five years .
You don't have any saved screeners yet
